سعر اريكسترا arixtra‏ 2.5 مجم /0.5 مل 10 حقن معبأة 2026

anticoagulant.low mwt heparin synthetic pentasaccharide

• The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Severe renal impairment (CrCl <30 mL/min); active major bleeding; bacterial endocarditis; thrombocytopenia with positive in-vitro anti-platelet antibody test in the presence of fondaparinux; body weight <50 kg (VTE prophylaxis in adults); history of serious hypersensitivity to ARIXTRA.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: epidural or spinal haematomas, possibly causing long-term or permanent paralysis, may occur in anticoagulated patients receiving neuraxial anaesthesia or spinal puncture; risk increased by indwelling epidural catheters and concomitant drugs affecting haemostasis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased haemorrhage risk with bleeding risk factors, renal impairment and in adults <50 kg; thrombocytopenia can occur; the needle guard contains dry natural rubber (latex).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Agents that enhance bleeding risk (e.g. NSAIDs, platelet inhibitors, other anticoagulants)Discontinue before starting fondaparinux unless essential; if co-administered, monitor closely for haemorrhage.DailyMed (U.S. National Library of Medicine)

• Published literature and postmarketing reports have not shown a clear association with adverse developmental outcomes; placental transfer is low; anticoagulants carry a risk of maternal and fetal haemorrhage.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on milk production; weigh benefits of breastfeeding against maternal need and potential infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Fondaparinux sodium: Binds selectively to antithrombin III and potentiates (about 300-fold) its neutralisation of factor Xa, interrupting the coagulation cascade and inhibiting thrombin formation; does not inactivate thrombin and has no known effect on platelet function (US prescribing information).